19 Jun 2014 Posted in News Release By Press Office
“I very much welcome the Prime Minister’s commitment to new action to accelerate progress on dementia medicines. The pharmaceutical industry is committed to addressing unmet medical need in neurodegenerative diseases and the pharmaceutical industry currently has hundreds of medicines in various stages of development to address dementia. However, Dementia poses particular challenges for companies investing in research and development because the symptoms emerge a decade or more after the first signs of disease develop. This means that clinical trials would need to take place over several years, at great cost, reducing patent life post-launch.
“The government can play a really crucial role in the acceleration of the research process by developing and participating in innovative funding models and progressive licensing approaches. Greater incentives could also take the form of patent rewards from medicine approval, not just from discovery, giving companies longer to invest, refine and produce the best treatments.
“Greater precompetitive collaboration is needed across sectors including public funders of research in experimental medicine to improve target validation, develop patient cohorts and novel methodologies, and it is good to see the government supporting such collaboration.
“Innovations have made it possible to manage or cure conditions such as HIV in a way that would have been unimaginable a couple of decades ago. Working with all stakeholders, we are confident that one day it will be possible to revolutionise the experience of dementia sufferers in the same way.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811